Grace Therapeutics CEO to Present at H.C. Wainwright Conference
Event summary
- Grace Therapeutics CEO Prashant Kohli to present at H.C. Wainwright 28th Annual Global Investment Conference on September 14-16, 2026.
- Presentation available on demand from September 11, 2026.
- GTx-104, Grace Therapeutics' lead asset for aSAH, has Orphan Drug Designation with 52 granted and pending patents.
- Company addressing FDA Complete Response Letter (CRL) for GTx-104 NDA resubmission.
The big picture
Grace Therapeutics' participation in the H.C. Wainwright conference comes as the company navigates regulatory challenges following its GTx-104 Complete Response Letter. The presentation represents an opportunity to reassure investors about the path forward for this Orphan Drug-designated treatment for aneurysmal Subarachnoid Hemorrhage (aSAH). The biopharma sector is closely watching how late-stage companies manage FDA hurdles while advancing novel drug delivery technologies.
What we're watching
- Regulatory Pathway
- Whether Grace Therapeutics can successfully address FDA CRL issues in GTx-104 NDA resubmission.
- Manufacturing Strategy
- The pace at which dual-source manufacturing strategy progresses with U.S.-based contract manufacturer.
- Investor Sentiment
- How conference presentation impacts investor confidence in GTx-104's commercial potential.